dextroamphetamine sulfate- dextroamphetamine sulfate solution
avadel generics, llc - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg in 5 ml - dextroamphetamine sulfate oral solution is indicated in: narcolepsy attention deficit disorder with hyperactivity: as an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympatho
procentra- dextroamphetamine sulfate solution
independence pharmaceuticals, llc - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg in 5 ml - dextroamphetamine sulfate oral solution is indicated in: narcolepsy attention deficit disorder with hyperactivity: as an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. known hypersensitivity to amphetamine products. during or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crisis may resu
siklos 1000mg tablets
nordic pharma ltd - hydroxycarbamide - tablet - 1gram
siklos 100mg tablets
nordic pharma ltd - hydroxycarbamide - tablet - 100mg
temazepam 20mg tablets
mawdsley-brooks & company ltd - temazepam - oral tablet - 20mg
temazepam 20mg tablets
waymade healthcare plc - temazepam - oral tablet - 20mg
temazepam 20mg tablets
de pharmaceuticals - temazepam - oral tablet - 20mg
temazepam 20mg tablets
ethigen ltd - temazepam - oral tablet - 20mg
temazepam 20mg tablets
national generics - temazepam - oral tablet - 20mg
temazepam 20mg tablets
b&s healthcare ltd - temazepam - oral tablet - 20mg